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Abstract
Transglutaminase 4 is a member of enzyme family that 
catalyzes calcium-dependent posttranslational mod-
ification of proteins. Although transglutaminase 4 has 
been shown to have prostate-restricted expression 
pattern, little is known about the biological function of 
transglutaminase 4 in human. To gain insight into its 
role in prostate, we analyzed the expression status of 
human transglutaminase 4 in benign prostate hyper-
plasia (BPH) and prostate cancer (PCa). Unexpectedly, 
RT-PCR and nucleotide sequence analysis showed 
four alternative splicing variants of transglutaminase 
4: transglutaminase 4-L, -M (-M1 and -M2) and -S. The 
difference between transglutaminase 4-M1 and -M2 is 
attributed to splicing sites, but not nucleotide size. The 
deduced amino acid sequences showed that trans-
glutaminase 4-L, -M1 and -M2 have correct open read-
ing frames, whereas transglutaminase 4-S has a trun-
cated reading frame. RT-PCR analysis of clinical sam-
ples revealed that transglutaminase 4-M and -S were 
detected in all tested prostate tissue (80 BPH and 48 
PCa). Interestingly, transglutaminase 4-L was found in 
56% of BPH (45 out of 80) and only in 15% of PCa (7 out 
of 48). However, transglutaminase 4-L expression did 
not correlate with serum prostate-specific antigen 
(PSA) level, prostate volumes or PSA densities. These 
results will provide a clue to future investigation aiming 
at delineating physiological and pathological roles of 
human transglutaminase 4.
Keywords: alternative splicing; prostate hyperplasia; 
prostatic neoplasms; transglutaminase 4
Introduction
Transglutaminases are a family of calcium- depen-
dent enzymes that consist of eight isoenzymes 
(transglutaminase 1-7 and factor XIIIa) and one 
evolutionary related protein (Band 4.2; Lorand and 
Graham, 2003). They participate in a variety of biolo-
gical phenomena associated with tissue protection, 
such as skin differentiation, blood coagulation and 
wound healing processes. During these processes, 
transglutaminases produce a high molecular weight 
of protein architecture conferring a resistance to 
mechanical stresses and proteolytic degradations 
(Griffin et al., 2002). The protein architecture is 
composed of protein polymers covalently cross- 
linked by isopeptide bond formation between 
peptide-bound glutamine and lysine residues.
    A number of studies concerning the nature of 
postejeculatory plug have recognized that a trans-
glutaminase isoenzyme secreted from prostate 
gland plays an important role in the reproduction 
biology of rodents (Williams-Ashman et al., 1972, 
1977; Williams-Ashman, 1984). Following studies 
have identified that copulatory plug is formed by 
transglutaminase 4 (prostate transglutaminase or 
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Figure 1. Identification of human transglutaminase 4 spliced variants in 
BPH tissues. RACE was performed on cDNA synthesized from BPH 
samples and resulted in three different-sized PCR products, 350 bp, 450 
bp and 600 bp.
TGP), a highly glycosylated protein enriched in 
dorsal prostate of rodents (Seitz et al., 1990). 
Interestingly, analysis of amino acid sequence 
determined by molecular cloning showed no 
putative signal sequence required for secretion (Ho 
et al., 1992). The copulatory plug formation has 
been thought to facilitate the fertilization by 
preventing seminal fluid from leaking out of vagina 
(Cukierski et al., 1991). In addition, transgluta-
minase 4 has been suggested to play an important 
role in suppression of sperm antigenicity in the 
female genital tract via incorporating seminal 
protein, such as uteroglobin, or polyamines into 
sperm cell surfaces (Mukherjee et al., 1983; 
Paonessa et al., 1984).
    In contrast to rodent transglutaminase 4, little 
has been known about physiological roles of 
human transglutaminase 4. Previous studies re-
vealed that human transglutaminase 4 showed 
prostate-restricted expression pattern (Dubbink et 
al., 1999), raising a possibility as a novel target for 
prostate-related diseases, particularly in prostate 
cancer, the second leading cause of cancer death 
in men (Savli et al., 2008). Interestingly, no 
expression of human transglutaminase 4 was 
observed in some prostate cancer cell lines 
(Dubbink et al., 1996), even though its promoter 
was shown to have basic transcriptional activity 
(Dubbink et al., 1998). Transcript analyses have 
showed that the expression of human trans-
glutaminase 4 is reduced in most metastatic 
prostate cancer specimens (An et al., 1999). Re-
cently, knockdown of transglutaminase 4 reduced 
invasive capacity in prostate cancer cells (Davies 
et al., 2007). Altogether, these results may provide 
helpful clues to understanding the role of human 
transglutaminase 4 in prostate cancer.
    Alternative splicing is an important mechanism 
to increase structural and functional diversity of 
proteins (Blencowe, 2006). In addition, growing 
evidence indicates that splicing variants can 
provide diagnostic and/or therapeutic targets for 
several cancers (Pajares et al., 2007). In this study, 
we found four mRNA variants of transglutaminase 
4 in human prostate tissues. Sequence analyses 
were carried out to demonstrate alternative splicing 
of transglutaminase 4. We also analyzed alter-
native splicing pattern in the tissue specimens 
obtained from benign prostate hyperplasia (BPH) 
and prostate cancer (PCa) patients.
Results
Identification of human transglutaminase 4 isoforms
We initially used a RT-PCR method to examine the 
expression of human transglutaminase 4 in BPH 
tissues. Unexpectedly, three different RT-PCR 
products were found in the tissue samples (Figure 
1). While a 450 bp fragment was the predicted size 
of band based on the sequence of human 
transglutaminase 4 cDNA (Grant et al., 1994; 
Dubbink et al., 1996), two products of 600 bp and 
350 bp were the unpredicted sizes.
    In order to assure the identity of each RT-PCR 
product, these fragments were cloned into pT7Blue 
vector. Sequence analysis revealed that a 450 bp 
fragment actually contains two different coding 
sequences of human transglutaminase 4, trans-
glutaminase 4-M1 and -M2 (Figure 2A). The sequ-
ence of transglutaminase 4-M1 was completely 
identical to that of human transglutaminase 4 as 
reported previously (Grant et al., 1994; Dubbink et 
al., 1996). The sequence of transglutaminase 4-M2 
was identical to that of transglutaminase 4-M1 with 
exception of a 4 bp segment (GTGA) insertion 
(Figure 2A, underlined). This insertion leads to a 
+2 frameshift, resulting in premature termination 
after six amino acids. However, interestingly, there 
are three consecutive initiation codons in the 5' 
end sequence (Figure 2A). It is thus possible that 
the reading frame of transglutaminase 4-M2 can 
be restored by alternative translation initiating at 
the third ATG codon.
    A 600 bp fragment (transglutaminase 4-L) also 
had coding sequences of transglutaminase 4. 
However, transglutaminase 4-L containing novel 
135 bp sequences (positions at 7447-7581 in 
Figure 3A), compared to transglutaminase 4-M1. 
The sequence of transglutaminase 4-L except an 
additional 135 bp fragment was completely 
identical to that of transglutaminase 4-M1. This 
insertion did not interfere with open reading frame 
of transglutaminase 4-M1, thereby providing addi-
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Figure 2. Comparison of nucleotide and amino acid sequences of human transglutaminase (TG) 4 isoforms. (A) Transglutaminase 4-M2 has four more 
nucleotide (GTGA, underlined) compare to transglutaminase 4-M1, which results in frameshift. Among three consecutive initiation codons 
(ATGATGGATG), transglutaminase 4-M1 is translated from first and transglutaminase 4-M2 is from third initiation codon. (B) Deduced amino acid se-
quence of transglutaminase 4-L. The underlined 45 amino acids are found only in transglutaminase 4-L, not in transglutaminase 4-M or -S. (C) Deduced 
amino acid sequence of transglutaminase 4-S. Transglutaminase 4-S shows 107 nucleotide deletion compared to transglutaminase 4-M1 and encodes 
truncated protein comprising 91 amino acids.
Figure 3. Structure and alternative 
splicing of human transglutaminase 
(TG) 4 gene. (A) Human trans-
glutaminase 4 gene has 15 exons 
and 14 introns. Exon 2, containing 
135 nuclotides, is found only in 
transglutaminase 4-L and Exon 4, 
comprising 107 nucleotides, is de-
leted in transglutaminase 4-S. (B) 
Nucleotide sequences of the 
exon-intron junction between exon 1 
and intron 1. The splicing site of 
transglutaminase 4-M2 is four-nu-
cleotide apart from the site of trans-
glutaminase 4-L and -M. The dots 
above the nucleotide sequences in-
dicate initiation codons. 
tional coding sequences. Thus, the open reading 
frame of transglutaminase 4-L can encode the 
polypeptide composed of 723 amino acid residues, 
indicating that transglutaminase 4-L has 45 addi-
tional amino acid residues (Figure 2B), compared 
to transglutaminase 4-M1. By contrast, sequence 
analysis of a 350 bp fragment (transglutaminase 
4-S) showed that 107 nucleotides were deleted 
from the transglutaminase 4-M1. This deletion 
caused in a shift of reading frame, leading to 
generating a stop codon (TGA). Thus, the open 
reading frame of transglutaminase 4-S may 
encode a prematurely terminated protein con-
sisting of 91 amino acid residues (Figure 2C).
Alternative splicing of the human transglutaminase 4 
gene
To investigate how human transglutaminase 4 
isoforms are generated, we next analyzed the 
genomic structure of human transglutaminase 4 
based on its sequence information obtained from 
human genome resources of NCBI. As shown in 
Figure 3A, the NCBI database shows that human 
transglutaminase 4 gene consists of 14 exons and 
13 introns and spans about 40 kb of genomic DNA 
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Figure 4. Schematic representation of alternatively spliced transcripts for 
human transglutaminase (TG) 4. 
Figure 5. Characterization of transglutaminase 4 isoforms expressed in yeast and HeLa cell lysate. (A) Yeast INVSc1 cells were transformed with 
pYes2.0 vector containing cDNA for hemagglutinin-tagged transglutaminase 4 isoform. Yeast lysates were analyzed by Western blot analysis using an-
ti-hemagglutinin antibody. (B) transglutaminase activities of yeast lysates were estimated by measuring incorporation of [14C]-putrescine to 
N,N'-dimethylcasein. Fold increase of transglutaminase activity is expressed as a relative value to that of vector transfected cells, which was normalized 
by protein level of transglutaminase 4 isoforms. (C) HeLa cells were transfected with cDNA for hemagglutinin-tagged transglutaminase 4 isoforms. Cell ly-
sates and lyophilized culture supernatants were analyzed by Western blot analysis using anti-hemagglutinin antibody. L, transglutaminase 4-L; M1, trans-
glutaminase 4-M1; M2, transglutaminase 4-M2.
on chromosome 3p21.33-p22 (region 44,891,131- 
44,931,097). Sequence alignment revealed that 
the novel 135 bp sequences of transglutaminase 
4-L is exactly matched with sequences on the 
intron 1 in NCBI database. Interestingly, putative 
splicing acceptor and donor sites were found in 
flanking region of the novel 135 bp sequences of 
transglutaminase 4-L. Thus, this finding indicates 
that a 135 bp fragment is a novel exon (designated 
as Exon 2 in Figure 3A) of transglutaminase 4. The 
nucleotide sequences of the exon-intron junction in 
the exon 2 showed that splice donor and acceptor 
sites followed the GT/AG rules (Mount, 1982).
    In a region of intron 1 splice donor sequence, 
two potential splicing junction consensus sequen-
ces were found in proximity. The transglutaminase 
4-M1 was spliced at a G/gt consensus site (Figure 
3B). In contrast, transglutaminase 4-M2, spliced at 
A/gt (Figure 3B), included the 4 nucleotides 
(GTGA) after the splice junction, resulting in shift of 
reading frame of transglutaminase 4-M2 form. 
Thus, the transglutaminase 4-M1 and -M2 forms 
are generated by selection of two consecutive 
splice consensus sequences located at intron 1. 
On the other hand, the exon 4 contains the 107 bp 
corresponding to the exact sequences that are 
deleted in transglutaminase 4-S. The schematic 
representation of alternative splicing of trans-
glutaminase 4 gene is illustrated in Figure 4. These 
results showed that exon 2 and 4 are responsible 
for the expression of the transglutaminase 4-L, -M 
and -S. In order to exclude the possibility of 
existence of different alleles, exon 2 and 4 were 
analyzed by PCR. Neither exon 2- or 4-deficient 
allele could be found in 100 normal human 
genomic DNA samples (data not shown).
Expression of transglutaminase 4 isoforms in yeast 
and HeLa cells
To examine whether each transglutaminase 4 
isoform is translated properly, hemagglutinin (HA)- 
tagged transglutaminase 4 isoforms were cloned to 
pYes2.0 vector and expressed in yeast INVsc1 
cells. Western blot analysis showed that trans-
glutaminase 4-L, -M1 and -M2 forms were ex-
pressed as single proteins and estimated mole-
cular weights were 93 kDa for transglutaminase 
4-L and 89 kDa for transglutaminase 4-M1 and -M2 
(Figure 5A). In addition, yeast extract transformed 
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BPH, Mean ± SD (range) PCa, Mean ± SD (range)
Number                     80                   48
Age (years)          71 ± 7.2 (51-86)             78 ± 6 (70-91)
Serum PSA (ng/ml)     9.40 ± 6.96 (0.51-29.25) 64.85 ± 35.09 (5.94-126)
Free PSA (ng/ml)     2.64 ± 2.71 (0.15-9.42)   14.11 ± 9.96 (0.52-29.57)
Prostate Volume (cc) 56.97 ± 24.30 (23-129.5) 49.11 ± 14.76 (35-67.9)
PSA density (ng/ml/cc)     0.16 ± 0.10 (0.02-0.39)     1.49 ± 1.12 (0.07-3.46)
Table 1. Comparison of clinical parameters between BPH and PCa patients.
Figure 6. Expression of human 
transglutaminase (TG) 4 isoforms in 
BPH. (A) Localization of primers 
used to amplify each spliced var-
iants of human transglutaminase 4. 
(B) Representative of RT-PCR anal-
ysis for transglutaminase 4 iso-
forms. cDNA synthesized from BPH 
tissues are amplified with TP-5/TP-4 
primers to detect transglutaminase 
4-L and -M isoforms.
with each transglutaminase 4 isoform exhibited 
significant transglutaminase activity compared to 
vector-transformed yeast extract (Figure 5B). 
Transglutaminase 4-L and transglutaminase 4-M1 
were also expressed as hemagglutinin-tagged 
forms in HeLa cells and detected as single protein 
in cell lysate. Interestingly, only transglutaminase 
4-M1 were detected in lyophilized culture super-
natant (Figure 5C), suggesting that transgluta-
minase 4-L was not secreted.
Differential alternative splicing of transglutaminase 4 
in BPH and PCa specimens
The expression of transglutaminase 4 mRNA 
isoforms was analyzed in prostate tissues by 
RT-PCR. The cDNAs were amplified using three 
pairs of specific primers designed to amplify only 
the transglutaminase 4-L form (375 bp with 
TP-3/TP-4), transglutaminase 4-L and -M forms 
(449 bp and 314 bp with TP-5/TP-4), and trans-
glutaminase 4-M and -S forms (441 bp and 334 bp 
with TP-6/TP-7), respectively (Figure 6A). Clinical 
parameters obtained from patients diagnosed as 
BPH or PCa were summarized in Table 1. RT-PCR 
analyses revealed that both transglutaminase 4-M 
and -S were detected in all tested tissues (80 BPH 
and 48 PCa tissues). Transglutaminase 4-L was 
found in 45 out of 80 BPH tissues (Figure 6B). On 
the other hand, it was only detected in 7 out of 48 
PCa tissues, indicating that the expression of 
transglutaminase 4-L decreased in PCa tissues 
compared to BPH tissues (Table 2). Nonetheless, 
transglutaminase 4-L expression did not correlate 
with serum PSA level, prostate volumes or PSA 
densities of BPH patients (Table 3).
Discussion
In this study, we provided the evidence that human 
transglutaminase 4 is alternatively spliced in pro-
state tissues. Four mRNA transcripts of transgluta-
minase 4, designated as transglutaminase 4-L, 
-M1, -M2 and -S, were identified by RT-PCR and 
sequence analyses. Identification of transgluta-
minase 4-L isoform contained a novel exon (exon 
2 in Figure 3A) indicates that human trans-
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Clinical parameter L & M (Mean ± SD)
M 
(Mean ± SD) P
Serum PSA (ng/ml)   9.74 ± 7.70   9.68 ± 7.15 0.663
Prostate volume (cc) 56.31 ± 24.01 56.51 ± 25.63 0.805
PSA density (ng/ml/cc)   0.15 ± 0.11   0.17 ± 0.11 0.535
Table 3. Clinical parameters of BPH with or without transglu-
taminase 4-L.
Transglutaminase 4 
isoforms BPH (%) Prostate Ca. (%)
L & M 45 (56)   7 (15)
M 35 (44) 41 (85)
80 (100) 48 (100)
Table 2. Expression of transglutaminase 4 isoforms in BPH and 
PCa (P ＜ 0.001).
glutaminase 4 gene consists of 15 exons and 14 
introns. The novel 45 amino acids corresponding 
to exon 2 have no significant amino acid sequence 
similarity with the other member of transgluta-
minase family. Secondary structure prediction 
analyses showed that the novel sequences have a 
long stretch of hydrophobic amino acid residues 
(about 20 amino acids), which may adopt a 
turn-helix-turn structural motif.
    Both transglutaminase 4-M1 and -M2 does not 
have exon 2. The generation of transglutaminase 
4-M1 or -M2 seems to depend on the selection of a 
splicing acceptor site during deletion of intron 2 in 
splicing events. Sequencing of 10 cDNA clones of 
transglutaminase 4-M showed that the frequency 
of occurrence of transglutaminase 4-M2 is equal 
with that of transglutaminase 4-M1 (data not 
shown), suggesting that transglutaminase 4-M1 
and -M2 may be equally expressed in human 
prostate. However, transglutaminase 4-M2 would 
use the third initiation codon to produce functional 
protein product, instead of the first ATG, as 
described before. It is of interest that the first 10 
nucleotides of human transglutaminase 4 (ATG-
ATGGATG) are identical to those of human 
transglutaminase 1 (Kim et al., 1992, Phillips et al., 
1990). Although human transglutaminase 1 also 
has two variants generated by utilizing different 
initiation codons, the amino acid sequence 
difference between two variants is resulted from 
allelic variation in the human population, instead of 
an alternative splicing mechanism (Kim et al., 
1992).
    The presence of several transcripts by 
alternative splicing may indicate functional diversity 
of human transglutaminase 4. However, little is 
known about its role in the prostate tissue. 
Interestingly, the clinical sample analyses showed 
the reduced expression of transglutaminase 4-L in 
prostate cancer. Thus, our data suggest that the 
change of alternative splicing of transglutaminase 
4 is associated with prostate cancer. Actually, 
growing evidence indicates that aberrant alter-
native splicing has been known to be associated 
with a variety of human diseases, particularly in 
cancers (Pajares et al., 2007). 
    A number of alternatively spliced genes have 
been reported in PCa. PSA is a member of 
kallikrein gene family and a well-known serum 
biomarker in PCa. PSA has at least 15 transcripts 
resulting from alternative splicing and alternative 
polyadenylation, and they code at least 8 different 
proteins (Heuze-Vourc'h et al., 2003). The investi-
gation about the changes of these spliced variants 
in PCa is required for more specific PSA screening 
test. Besides PSA, other members of kallikrein 
gene family, including KLK2, KLK3, KLK11, and 
KLK15, have more than one spliced variant and 
were reported to be up-regulated in PCa (Reynolds, 
2008). For example, KLK11 has two alternatively 
spliced isoforms and the low expression of prostate 
type variant in PCa is associated with higher tumor 
stage, Gleason score, and tumor grade (Nakamura 
et al., 2003). In addition, loss of a certain spliced 
variant of fibroblast growth factor receptor 2 
(FGF-R2) is correlated with androgen insensitivity 
(Carstens et al., 1997), and truncated isoform of 
VEGF receptor flt-4 (VEGFR3) increases in PCa 
with lymph node involvement (Stearns et al., 
2004). Therefore, detection of splicing variants can 
be employed for diagnosis and prognosis 
prediction in PCa.
    While rodent transglutaminase 4 has a crucial 
role in fertilization by forming copulatory plug, the 
function of human transglutaminase 4 is still 
obscure. Since human transglutaminase 4 is 
secreted form prostate and a constituent of semen, 
it has been suggested to have a role in human 
fertilization by suppressing sperm antigenicity or 
unknown mechanism (Mukherjee et al., 1983, 
Paonessa et al., 1984). Moreover, transgluta-
minase 4 showed prostate-restricted expression 
pattern (Dubbink et al., 1999) and transgluta-
minase 2, another transglutaminase family mem-
ber, has been associated with apoptosis and 
cancer cell survival (Fesus and Szondy, 2005). 
Therefore, transglutaminase 4 has been suspected 
to be involved in BPH and PCa pathogenesis. Our 
result showed loss of transglutaminase 4-L variant 
in PCa samples (Table 2), corroborating the 
previous report that showed down-regulation of 
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transglutaminase 4 expression in metastatic PCa 
samples (An et al., 1999). Therefore, down-re-
gulation of transglutaminase 4, especially trans-
glutaminase 4-L, is probably associated with 
cancer development and progression. By contrast, 
recent studies showed that overexpression of 
transglutaminase 4 in PCa cells increased ad-
hesion of cancer cells to endothelial cells and 
reduced barrier function of endothelial cells (Jiang 
et al., 2009). Conversely, knock-down of transglu-
taminase 4 in PCa cells decreased invasiveness 
and tumor-endotheilal cell interactions (Davies et 
al., 2007; Jiang et al., 2009). Because trans-
glutaminase 4-M1, which is a NCBI reference 
sequence, was used in these studies, alternatively 
spliced transglutaminase 4 isoforms could help to 
explain these contradictory observations on the 
tumorigenicity and invasiveness of PCa cells. 
Nevertheless, the role of each transglutaminase 4 
spliced variant in PCa need to be determined.
    Although transglutaminase 4 is known as 
secreted protein, when expressed in HeLa cell, 
transglutaminase 4-L was not detected in culture 
supernatants (Figure 5C). Therefore, the difference 
of cellular localization is one of factors that confer 
different functions on each spliced variant because 
enzymes in different location probably use different 
substrate partners.
    In conclusion, we discovered four alternatively 
spliced variants of transglutaminase 4 (transglu-
taminase 4-L, -M1, -M2 and -S) and found that loss 
of transglutaminase 4-L isoform is associated with 
PCa in prostate samples. Though the exact patho-
physiological functions of these spliced variants 
need to be determined, these results suggest 
potential role of transglutaminase 4 in PCa progre-
ssion and shed light on physiological and patho-
logical functions of human transglutaminase 4.
Methods
Prostate specimens and clinical parameters
Human prostate specimens were obtained from the 
patients diagnosed to have BPH or PCa by transurethral 
resection of prostate or radical prostatectomy. Tissues 
were immediately frozen in liquid nitrogen and stored at 
-80oC until use. H&E staining of prostate tissues were 
performed for pathological examination. The study was 
approved by the Institutional Review Board of Seoul 
National University Hospital and informed consent was 
obtained from each patient.
    Total and free PSA was assayed from serum of patients 
using I125-labeled anti-PSA monoclonal antibody (ELSA- 
PSA2 kit; CIS-bio Co.). To calculate prostate volume, 
transrectal ultrasonography was performed using a HDI 
3000 scanner with an endocavitary multifrequency 5- to 
9-MHz transducer (ATL Co.). Volume of prostate was 
calculated using the three main diameters of the gland, in 
which the volume equals 0.5 × (L × W × H), where L is 
the maximum cephalocaudal length in longitudinal view, W  
is the maximum transverse length in transaxial view and H  
is the maximum anteroposterior length in longitudinal view 
(Terris and Stamey, 1991). The PSA density was calcu-
lated as PSA (ng/ml) divided by prostate volume (cc).
RT-PCR amplification and cloning of human 
transglutaminase 4 isoforms
Total RNA was isolated from BPH specimens using acid 
guanidinium thiocyanate-phenol, chloroform extraction 
method (Chomczynski and Sacchi, 1987). Rapid ampli-
fication of cDNA ends (RACE) was employed to amplify 
the 5' end of cDNAs (Frohman et al., 1988). Random 
primed first strand cDNA was synthesized from 500 ng of 
total RNA by using the Superscript reverse transcriptase kit 
(Invitrogen), and a stretch of dG residues was added to the 
3' end using terminal deoxynucleotidyl transferase (Pro-
mega). The first PCR was performed with 25 pmol of 
oligo(dC)17 and TP-1 (5'-ctcaaactgaccaaagttcca-3'; re-
verse) primers using dG tailed RT reaction product. The 
second PCR was performed with a oligo(dC)17 and TP-2 
(5'-acaccatgggttgaagaga-3'; reverse) primers as follows. 
The samples were heated to 95oC for 5 min, followed by 
35 cycles of denaturation at 94oC (0.5 min), annnealing at 
48oC (0.5 min), and extension at 72oC (1.5 min). Following 
the final extension at 72oC (10 min), PCR products were 
analyzed by 1.5% agarose gel electrophoresis, purified, 
and directly ligated into pT7Blue T-vector (Novagen). 
Colonies containing inserts were selected, and sequenced 
using primers to the T7 and U19 regions of the plasmid 
vector.
Expression of transglutaminase 4 isoforms in yeast 
and HeLa cells
cDNAs of transglutaminase 4-L, -M1 and -M2 were cloned 
into pYES2.0 (Invitrogen) or pcDNA3 (Invitrogen) for ex-
pression in yeast or in mammalian cell, respectively. Each 
transglutaminase 4 isoform was tagged with hemagglutinin 
epitope for detection of protein. For yeast expression, 
INVsc1 cells (Invitrogen) were transformed by Lithium 
acetate/single stranded-DNA/Polyethylglycol method (Jeon 
et al., 2003) and grown in SD medium (0.67% Yeast 
nitrogen base without amino acids, 2% glucose and 
0.065% CSM-URA). Expression of protein was induced by 
incubation with YPG medium (1% yeast extract, 2% 
bacto-peptone and 2% galactose) for 4 h. For mammalian 
cell expression, HeLa cells were transfected with transglu-
taminase 4 isoforms in pcDNA3 using LipofectAMINE 
reagent (Invitrogen) according to manufacturer's instruc-
tions. After 48 h of transfection, cell lysates and lyophilized 
culture supernatants were analyzed for protein expression.
Western blot analysis
Yeast cell was homogenized using glass beads in the 
homogenization buffer (50 mM Tris-Cl, pH 7.5, 250 mM 
sucrose, 0.2 mM MgSO4, 1 mM EDTA, 10 mM DTT) 
containing protease inhibitor cockail (Roche). HeLa cells 
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were lysed in the buffer containing 50 mM Tris-Cl, pH 8.0, 
150 mM NaCl, 1% Triton X-100 and protease inhibitor 
cocktail. The culture supernatant of HeLa cells was 
lyophilized and reconstituted with PBS. The samples were 
centrifuged at 14,000 × g for 10 min at 4oC, and the 
protein concentration of the supernatant was determined 
by BCA method. Each sample was resolved by SDS-PAGE 
and transferred onto nitrocellulose membrane. After 
treating for 1 h with 5% skim milk in Tris-buffered saline, 
the membrane was incubated with antibodies for 
hemagglutinin (Roche) or actin (Sigma) for 2 h. The 
membranes were washed, incubated with HRP-conjugated 
secondary antibody, and then developed using chemilumi-
nescence substrate solution as instructed by the 
manufacture (Pierce).
Transglutaminase activity assay
Transglutaminase activity of yeast lysate was measured by 
estimating incorporation of [14C]-putrescine (Amersham) to 
N,N'-dimethylcasein (Sigma). Yeast lysate (500 μg) was 
incubated with N,N'-dimethylcasein and 500 nCi of 
[14C]-putrescine in reaction buffer (50 mM Tris-acetate, pH 
7.5, 10 mM CaCl2, 5 mM DTT, 150 mM NaCl, 0.5% Triton 
X-100, 0.5 mM EDTA) for 1 h at 37oC. After precipitated 
with trichloroacetic acid, samples were bound to filter 
paper, and radioreactivity was assessed by scintilation 
counting. Transglutaminase activity is expressed as a 
relative value to that of vector transfected cells, which was 
normalized by protein level of transglutaminase 4 isoforms.
RT-PCR analysis with BPH and PCa specimens
RNA preparation and reverse transcription were performed 
using BPH (80 cases) and PCa (48 cases) specimens. 
PCR was carried out with TP-3 (5'-cactttgttgcccaggctg-3'; 
forward)/TP-4 (5'-ctgccagttgtagtggtct-3'; reverse), TP-5 (5'- 
agagatagagtcttccctg-3'; forward)/TP-4 and TP-6 (5'-caaa-
cgagcagtcctgtgt-3'; forward)/TP-7 (5'-gcatttgatacttctggca-3'; 
reverse) for detecting transglutaminase 4-L, -L/M and -M/S 
forms, respectively (Figure 5A). The pre-heated samples 
were placed in 35 cycles consisting of denaturation at 94oC 
(0.5 min), annnealing at 48oC (0.5 min), and extension at 
72oC (1.5 min). Following the final extension at 72oC (10 
min), PCR products were analyzed by 1.5% agarose gel 
electrophoresis.
Statistical analysis
The statistical analyses were performed by the SPSS 
software (Statistical Package for the Social Sciences, 
SPSS Inc). Comparison of transglutaminase 4-L expre-
ssion between BPH and PCa was performed with chi- 
square test. Comparisons of serum PSA, prostate volume 
and PSA density between transglutaminase 4-L expressed 
and non-expressed BPH patients were done with the t test. 
P-values less than 0.05 were considered significant.
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